U.S. Capital Wealth Advisors LLC Makes New Investment in InMode Ltd. (NASDAQ:INMD)

U.S. Capital Wealth Advisors LLC bought a new position in InMode Ltd. (NASDAQ:INMD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 94,035 shares of the healthcare company's stock, valued at approximately $2,091,000. U.S. Capital Wealth Advisors LLC owned about 0.11% of InMode at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in INMD. Exchange Traded Concepts LLC purchased a new stake in InMode in the third quarter worth approximately $27,000. Cambridge Investment Research Advisors Inc. boosted its holdings in InMode by 32.9% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 35,018 shares of the healthcare company's stock worth $1,067,000 after purchasing an additional 8,667 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in InMode by 10.5% in the third quarter. Bank of New York Mellon Corp now owns 255,470 shares of the healthcare company's stock worth $7,782,000 after purchasing an additional 24,264 shares during the last quarter. Park Avenue Securities LLC boosted its holdings in InMode by 18.1% in the third quarter. Park Avenue Securities LLC now owns 12,516 shares of the healthcare company's stock worth $381,000 after purchasing an additional 1,919 shares during the last quarter. Finally, Whittier Trust Co. raised its position in InMode by 4.1% in the third quarter. Whittier Trust Co. now owns 98,396 shares of the healthcare company's stock worth $2,996,000 after acquiring an additional 3,859 shares during the period. Hedge funds and other institutional investors own 68.04% of the company's stock.

InMode Price Performance

Shares of INMD stock traded up $0.28 during trading hours on Friday, hitting $17.64. The stock had a trading volume of 1,596,228 shares, compared to its average volume of 1,636,185. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of 8.36 and a beta of 2.20. InMode Ltd. has a one year low of $16.72 and a one year high of $48.25. The stock's 50-day moving average price is $19.92 and its two-hundred day moving average price is $21.35.

InMode (NASDAQ:INMD - Get Free Report) last released its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.05. The business had revenue of $126.80 million for the quarter, compared to the consensus estimate of $124.77 million. InMode had a return on equity of 27.66% and a net margin of 38.84%. The company's revenue was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.69 EPS. As a group, equities research analysts predict that InMode Ltd. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

INMD has been the topic of several recent research reports. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a research report on Friday. Barclays decreased their price target on shares of InMode from $34.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, April 12th. Finally, UBS Group increased their price target on shares of InMode from $24.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 14th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $32.80.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.